Citations

Showing 10 of 108083 citations.

A mutational comparison of adult and adolescent and young adult (AYA) colon cancer
Tricoli, James V. , Boardman, Lisa A. , Patidar, Rajesh , Jang, Jin Sung , Walsh, William D., McGregor, Paul M., Camalier, Corinne E., Mehaffey, Michele G., Furman, Wayne L. , Bahrami, Armita , Lih, Chih‐Jian, Conley, Barbara A. , Khan, Javed , Jang, Jin S, Boardman, Lisa , Sindiri, Sivasish , Williams, P. Mickey

Mayo Clinic

Cancer | November 30, 2017 | Volume: 124 | Issue: 5 | Pages: 1070-1082

10.1002/cncr.31136 | PMID 29194591 Get It

BACKGROUND It is possible that the relative lack of progress in treatment outcomes among adolescent and young adult (AYA) patients with cancer is caused by a difference in disease biology compared with the corresponding diseases in younger and older individuals. There is evidence that colon cancer is more aggressive and has a poorer prognosis in AYA patients than in older adult patients. METHODS To further understand the molecular basis for this difference, whole‐exome sequencing was conducted on a cohort of 30 adult, 30 AYA, and 2 pediatric colon cancers. RESULTS A statistically significant difference in mutational frequency was observed between AYA and adult samples in 43 genes, including ROBO1 , MYC binding protein 2 ( MYCBP2 ), breast cancer 2 (early onset) ( BRCA2 ), MAP3K3, MCPH1, RASGRP3, PTCH1, RAD9B, CTNND1, ATM, NF1 ; KIT, PTEN , and FBXW7 . Many of these mutations were nonsynonymous, missense, stop‐gain, or frameshift mutations that were damaging. Next, RNA sequencing was performed on a subset of the samples to confirm the mutations identified by exome sequencing. This confirmation study verified the presence of a significantly greater frequency of damaging mutations in AYA compared with adult colon cancers for 5 of the 43 genes ( MYCBP2, BRCA2, PHLPP1, TOPORS , and ATR ). CONCLUSIONS The current results provide the rationale for a more comprehensive study with a larger sample set and experimental validation of the functional impact of the identified variants along with their contribution to the biologic and clinical characteristics of AYA colon cancer. Cancer 2018;124:1070‐82. © 2017 American Cancer Society .
Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a “Traceback” approach
Moss, Haley , Samimi, Goli , Sherman, Mark E. , Moss, Haley A , Havrilesky, Laura Jean , Myers, Evan R.

Mayo Clinic

Genetic Epidemiology | November 30, 2017 | Volume: 42 | Issue: 1 | Pages: 117-122

10.1002/gepi.22095 | PMID 29193313 Get It

ABSTRACTU.S. guidelines recommend BRCA1/2 mutation testing for women diagnosed with high‐grade ovarian cancer (HGOC) to increase recognition of carriers, but most remain unidentified and at risk. Accordingly, an approach termed “Traceback” has been proposed in which probands are retrospectively identified by testing archived pathology specimens, and family members are traced to provide genetic counseling and testing. We used population‐based data to estimate the number of family members who might be contacted through such a program. We used incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program to estimate the number of women diagnosed with HGOC from 2005 to 2016, and census data to estimate the number of spouses, offspring, and siblings (both sexes). Using overall survival for HGOC from SEER and all‐cause mortality rates from the Centers for Diseases Control and Prevention, we estimated the number of patients, spouses, offspring, and siblings of HGOC cases living in 2017. Due to the high mortality rate of HGOC, consent from living probands may be possible in only 42% of the cases; consent to test pathology specimens would need to be sought from next of kin for the remainder. In 2017, an estimated 406,919 living next of kin (spouses, siblings, offspring) would be available for potential consent. Testing archived ovarian cancer pathology specimens may enable the identification of BRCA1/2 mutation carriers, but consent from next of kin would be required in in 58% of cases. Although Traceback offers the possibility of identifying unaffected BRCA1/2 mutation carriers, pilot feasibility studies that include assessment of methods to secure consent are needed.
Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study
Rosenberry, Terrone L. , Brazzolotto, Xavier , Macdonald, Ian R. , Wandhammer, M., Trovaslet-Leroy, M., Darvesh, Sultan , Nachon, Florian

Mayo Clinic

Molecules | November 30, 2017 | Volume: 22 | Issue: 12 | Pages: 2098

10.3390/molecules22122098 | PMID 29186056 Get It

Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) hydrolyze the neurotransmitter acetylcholine and, thereby, function as coregulators of cholinergic neurotransmission. Although closely related, these enzymes display very different substrate specificities that only partially overlap. This disparity is largely due to differences in the number of aromatic residues lining the active site gorge, which leads to large differences in the shape of the gorge and potentially to distinct interactions with an individual ligand. Considerable structural information is available for the binding of a wide diversity of ligands to AChE. In contrast, structural data on the binding of reversible ligands to BChE are lacking. In a recent effort, an inhibitor competition approach was used to probe the overlap of ligand binding sites in BChE. Here, we extend this study by solving the crystal structures of human BChE in complex with five reversible ligands, namely, decamethonium, thioflavin T, propidium, huprine, and ethopropazine. We compare these structures to equivalent AChE complexes when available in the protein data bank and supplement this comparison with kinetic data and observations from isothermal titration calorimetry. This new information now allows us to define the binding mode of various ligand families and will be of importance in designing specific reversible ligands of BChE that behave as inhibitors or reactivators.
Adaptive Servo-Ventilationf for Central Sleep Apnoea in Systolic Heart Failure: Results of the Major Substudy of SERVE-HF
Cowie, Martín , Woehrle, Holger , Vettorazzi, Eik , Lezius, Susanne , Köenig, Wolfgang , Weidemann, Frank, Smith, Gillian, Angermann, Christiane, d’Ortho, Marie‐Pia , Erdmann, Erland , Lévy, Patrick , Simonds, Anita K. , Zannad, Faı̈ez , Teschler, Helmut, Lévy, Patrick , Wegscheider, Karl , Somers, Virend K. , Koenig, Wolfgang , Cowie, Martin R

Mayo Clinic

European Journal of Heart Failure | November 30, 2017 | Volume: 20 | Issue: 3 | Pages: 536-544

10.1002/ejhf.1048 | PMID 29193576 Get It

Abstract Aims The SERVE-HF trial investigated the impact of treating central sleep apnoea (CSA) with adaptive servo-ventilation (ASV) in patients with systolic heart failure. A preplanned substudy was conducted to provide insight into mechanistic changes underlying the observed effects of ASV, including assessment of changes in left ventricular function, ventricular remodelling, and cardiac, renal and inflammatory biomarkers. Methods and results In a subset of the 1325 randomised patients, echocardiography, cardiac magnetic resonance imaging (cMRI) and biomarker analysis were performed at baseline, and 3 and 12 months. In secondary analyses, data for patients with baseline and 12-month values were evaluated; 312 patients participated in the substudy. The primary endpoint, change in echocardiographically determined left ventricular ejection fraction from baseline to 12 months, did not differ significantly between the ASV and the control groups. There were also no significant between-group differences for changes in left ventricular dimensions, wall thickness, diastolic function or right ventricular dimensions and ejection fraction (echocardiography), and on cMRI (in small patient numbers). Plasma N-terminal pro B-type natriuretic peptide concentration decreased in both groups, and values were similar at 12 months. There were no significant between-group differences in changes in cardiac, renal and systemic inflammation biomarkers. Conclusion In patients with systolic heart failure and CSA, addition of ASV to guideline-based medical management had no statistically significant effect on cardiac structure and function, or on cardiac biomarkers, renal function and systemic inflammation over 12 months. The increased cardiovascular mortality reported in SERVE-HF may not be related to adverse remodelling or worsening heart failure.
National Trends in Admission and In‐Hospital Mortality of Patients With Heart Failure in the United States (2001–2014)
Akintoye, Emmanuel , Briasoulis, Αlexandros , Egbe, Alexander C. , Kushwaha, Sudhir S. , Levine, Diane , Afonso, Luis , Weinberger, Jarrett, Dunlay, Shannon M. , Kushwaha, Sudhir, Briasoulis, Alexandros , Mozaffarian, Dariush

Mayo Clinic

Journal of the American Heart Association | November 30, 2017 | Volume: 6 | Issue: 12 | Pages: No page available

10.1161/jaha.117.006955 | PMID 29187385 Get It

Background To investigate heart failure ( HF ) hospitalization trends in the United States and change in trends after publication of management guidelines. Methods and Results Using data from the National Inpatient Sample and the US Census Bureau, annual national estimates in HF admissions and in‐hospital mortality were estimated for years 2001 to 2014, during which an estimated 57.4 million HF ‐associated admissions occurred. Rates (95% confidence intervals) of admissions and in‐hospital mortality among primary HF hospitalizations declined by an average annual rate of 3% (2.5%–3.5%) and 3.5% (2.9%–4.0%), respectively. Compared with 2001 to 2005, the average annual rate of decline in primary HF admissions was more in 2006 to 2009 (ie, 3.4% versus 1.1%; P =0.02). In 2010 to 2014, primary HF admission continued to decline by an average annual rate of 4.3% (95% confidence interval, 3.9%–5.1%), but this was not significantly different from 2006 to 2009 ( P =0.14). In contrast, there was no further decline in in‐hospital mortality trend after the guideline‐release years. For hospitalizations with HF as the secondary diagnosis, there was an upward trend in admissions in 2001 to 2005. However, the trend began to decline in 2006 to 2009, with an average annual rate of 2.4% (95% confidence interval, 0.8%–4%). Meanwhile, there was a consistent decline in in‐hospital mortality by an average annual rate of 3.7% (95% confidence interval, 3.3%–4.2%) during the study period, but the decline was more in 2006 to 2009 compared with 2001 to 2005 (ie, 5.4% versus 3.4%; P <0.001). Beyond 2009, admission and in‐hospital mortality rates continued to decline, although this was not significantly better than the preceding interval. Conclusions From 2001 to 2014, HF admission and in‐hospital mortality rates declined significantly in the United States; the greatest improvements coincided with the publication of the 2005 American College of Cardiology/American Heart Association HF guidelines.
In Memoriam: Gordon K. Danielson (1931-2017)
Dearani, Joseph A. , Dearani, Joseph A.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | November 29, 2017 | Volume: 8 | Issue: 6 | Pages: 663-664

10.1177/2150135117743187 | PMID 29187099 Get It

Healthy Immigrant Families: Randomized Controlled Trial of a Family-Based Nutrition and Physical Activity Intervention
Wieland, Mark L. , Hanza, Marcelo M., Weis, Jennifer A., Clark, Matthew M. , Sloan, Jeff A. , Novotny, Paul J. , Njeru, Jane W. , Abbenyi, Adeline, Levine, James A. , Goodson, Miriam, Capetillo, Graciela D. Porraz, Hared, Abdullah, Nigon, Julie A., Sia, Irene G. , Hanza, Marcelo M M, Patten, Christi A. , Wieland, Mark L , Meiers, Sonja J. , Capetillo, Graciela Porraz, Osman, Ahmed , Sia, Irene G

Mayo Clinic

American Journal of Health Promotion | November 29, 2017 | Volume: 32 | Issue: 2 | Pages: 473-484

10.1177/0890117117733342 | PMID 29186984 Get It

Purpose: To evaluate a healthy eating and physical activity intervention for immigrant families, derived through community-based participatory research. Design: The Healthy Immigrant Families study was a randomized controlled trial with delayed intervention control group, with families as the randomization unit. Setting: US Midwest city. Participants: Participants were recruited by community partners from Hispanic, Somali, and Sudanese immigrant communities. Intervention: Family health promoters from participating communities delivered 6 healthy eating modules, 4 physical activity modules, and 2 modules synthesizing information in 12 home visits (60-90 minutes) within the first 6 months. Up to 12 follow-up phone calls to each participant occurred within the second 6 months. Measures: Primary measures were dietary quality measured with weekday 24-hour recall and reported as Healthy Eating Index score (0-100) and physical activity measured with accelerometers (14 wear days) at baseline, 6, 12, and 24 months. Results: In total, 151 persons (81 adolescents and 70 adults; 44 families) were randomly assigned. At 12 months, significant improvement occurred in Healthy Eating Index scores for adults in the intervention group compared with controls (change, +8.6 vs −4.4; P < .01) and persisted at 24 months (+7.4 from baseline; P < .01). No differences were observed for adolescents and no significant differences occurred between groups for physical activity. Conclusion: This intervention produced sustained dietary quality improvement among adults but not among adolescents. Program outcomes are relevant to communities working to decrease cardiovascular risk among immigrant populations.
Increased Whole Blood Viscosity Is Associated with the Presence of Digital Ulcers in Systemic Sclerosis: Results from a Cross-Sectional Pilot Study
Korsten, Peter , Niewold, Timothy B. , Zeisberg, Michael , Utset, Tammy O., Zachary, Lawrence S., Sweiss, Nadera , Volkov, Suncica , Korsten, Peter , Cho, Daniel

Mayo Clinic

Autoimmune Diseases | November 29, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-5

10.1155/2017/3529214 | PMID 29318042 Get It

Objective. To investigate the role of whole blood viscosity in digital ulcer (DU) development in patients with diffuse and limited Systemic sclerosis.Methods. A convenience sample of patients with Systemic sclerosis (SSc) was selected from the adult Rheumatology clinic at the University of Chicago. The study group consisted of patients with SSc (with ulcers present, a history of ulcers, and no ulcers); the control group consisted of matched healthy Rheumatology clinic staff. WBV was measured using a scanning capillary viscometer at different shear rates (1–1000 1/s).Results. Whole blood viscosity as measured by a scanning capillary viscometer was increased in patients with SSc compared to healthy controls (p<0.0001). Additionally, patients with present DU had significantly higher whole blood viscosity when compared to patients with a history of DU and patients with no history of DU (p<0.0001). These findings were most pronounced at lower shear rates between 1 and 10 1/s.Conclusion. Whole blood viscosity might be a contributing factor in DU development in patients with SSc. Further studies with larger patient cohorts are required to fully evaluate how increased WBV contributes to the development of DU and whether the currently available treatment options improve the microcirculation by influencing WBV.
Early Parental Abuse and Daily Assistance to Aging Parents With Disability: Associations With the Middle-Aged Adults’ Daily Well-being
Liu, Yin , Bangerter, Lauren R. , Almeida, David M. , Kong, Jooyoung , Zarit, Steven Howard

Mayo Clinic

The Journals of Gerontology: Series B | November 29, 2017 | Volume: 73 | Issue: 5 | Pages: e59-e68

10.1093/geronb/gbx173 | PMID 29325175 Get It

Noncardiovascular Disease and Critical Care Delivery in a Contemporary Cardiac and Medical Intensive Care Unit
Liszkowski, Mark , Cercek, Bojan, Goldfarb, Michael , Goldfarb, Michael , Diepen, Sean van , Jentzer, Jacob C. , Pedraza, Isabel

Mayo Clinic

Journal of Intensive Care Medicine | November 29, 2017 | Volume: 34 | Issue: 7 | Pages: 537-543

10.1177/0885066617741873 | PMID 29187011 Get It

Background: Noncardiovascular comorbidities and critical illness are increasing in cardiovascular intensive care units (CICUs). There are limited data comparing critical care delivery, resource utilization, and costs between contemporary CICUs and medical intensive care units (MICUs). Methods: All CICU (n = 6967; 22 748 patient-days) and MICU (n = 10 892; 39 211 patient-days) admissions to Cedars-Sinai Medical Center, a tertiary care academic medical center, between January 2011 and December 2016 were reviewed. Both the CICU and MICU admitted patients for primary cardiovascular or medical conditions during the study period, but not for postoperative surgical care. Results: Patients admitted to the CICU were more frequently older, male, and had more preexisting cardiac disease ( P < .0001). More than one-fifth (21.4%) of CICU patients had a noncardiovascular primary admission diagnosis, compared to 89.2% of MICU patients. Cardiovascular intensive care unit patients had lower Acute Physiology and Chronic Health Evaluation III scores (51.1 [19.9] vs 61.1 [24.9], P < .0001) and shorter median hospital length of stay ( P < .001), but not in-unit stay, as compared to MICU patients. Mechanical ventilation, vasopressors, inotropes, renal replacement therapy, and/or blood transfusion were required in 35.0% of CICU patients compared with 62.2% of MICU patients ( P < .0001). The unit mortality rate was lower for CICU than MICU patients (4.8% vs 13.0%, P < .0001), as was the hospital mortality rate (9.3% vs 21.6%, P < .0001). The standardized mortality ratio was 0.73 for the CICU and 0.86 for the MICU. There was no difference in the mean direct cost of care per patient-day between the CICU and MICU ($4011 USD [376] vs $3990 USD [214], P = .77). Conclusions: The burden of noncardiovascular diseases and the requirement for critical care therapies are high in contemporary CICU patients but remain lower compared to the MICU population. Our findings support the growing complexity of care in tertiary CICUs. Further studies are required to explore the association between critical care delivery and outcomes in this evolving population.